Optibrium partners with FMC Corporation to transform agrochemical discovery
CAMBRIDGE, UK and CAMBRIDGE, US 14 May 2024 – Optibrium, a leading developer of software and AI solutions for drug…
The models in Cerella estimate the uncertainty in every individual prediction. This is one of the big advantages of the Alchemite method underlying Cerella.
In some cases, the uncertainty in a prediction is so large that it cannot distinguish confidently between the highest and lowest observed value for the property in the training data set. You can consider this as the compound lying far outside of the domain of applicability of the model. In this case, Cerella will not return a predicted value.
More resources
Transforming drug discovery with deep learning imputation
In European Biopharmaceutical Review, Optibrium’s CEO Dr Matthew Segall discusses how we can elevate drug discovery with deep learning imputation. He shares…
AI in the drug discovery industry
Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses…
